SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: Cbdpotential
Search This Board: 
Last Post: 11/21/2017 1:15:13 PM - Followers: 152 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

SureTrader
Interactive Brokers Advertisement
IDRA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA News: Proxy Statement (definitive) (def 14a) 11/17/2017 04:33:31 PM
IDRA News: Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at t... 11/09/2017 07:30:00 AM
IDRA News: Quarterly Report (10-q) 11/06/2017 04:06:10 PM
IDRA News: Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 11/06/2017 04:02:00 PM
IDRA News: Current Report Filing (8-k) 10/26/2017 05:13:28 PM
PostSubject
#3097   Nice move today Stay GREEN $idra :-D Cbdpotential 11/21/17 01:15:13 PM
#3096   IDRA Proxy statement. Citrati 11/17/17 11:27:48 PM
#3095   I have a full confidence on management , youssef 11/16/17 07:47:38 PM
#3094   Same here, in holddown mode for the other steppe 11/16/17 04:03:34 PM
#3093   Wouldn't hurt my feelings at all for the Citrati 11/16/17 01:06:56 PM
#3092   No I have enough of the other one youssef 11/16/17 09:04:59 AM
#3091   Hi Youssef, steppe 11/16/17 08:47:08 AM
#3090   I m buying idra weekly youssef 11/15/17 09:15:17 PM
#3089   Just a thought, if anyone still follows IDRA. Citrati 11/15/17 11:21:04 AM
#3088   Yes. Wish I had waited a couple more noretreat 11/10/17 04:12:05 PM
#3087   Lot of people unhappy with the capital raise. Citrati 11/10/17 03:40:56 PM
#3086   I think that is good news as well. Stockdoggy 11/10/17 12:24:45 PM
#3085   FYI short interest, got this from WSJ website noviceinvestor08 11/10/17 07:47:11 AM
#3084   * * $IDRA Video Chart 11-09-17 * * ClayTrader 11/09/17 04:38:30 PM
#3083   I'm guessing you like your average price here Citrati 11/09/17 02:32:03 PM
#3082   Too many good ones! Perspective is tough Patience is absolutely Cbdpotential 11/09/17 10:44:01 AM
#3081   Thankyou for closing the gap. See what happens Citrati 11/09/17 10:35:51 AM
#3080   Wish I could buy more! :-D Cbdpotential 11/09/17 10:27:28 AM
#3079   Buy some more Cbd and get that gap Citrati 11/09/17 10:13:11 AM
#3078   This is why a plan is needed. Otherwise Citrati 11/07/17 11:51:59 AM
#3077   Very nice recovery here imo $idra Green :-D Cbdpotential 11/07/17 10:09:17 AM
#3076   Volume seems to be more consistently above avg Farmmarket1 11/06/17 10:21:42 PM
#3075   Gap closing continues. Pretty good sign of how Citrati 11/06/17 03:17:54 PM
#3074   Thanks NR. Citrati 11/06/17 10:10:45 AM
#3073   regarding your last comment....RIGHT NOW is a good time. noretreat 11/06/17 10:05:52 AM
#3072   I expect it to double. But honestly next Rcoombz 11/03/17 04:25:31 PM
#3071   Added yesterday Under 1.7 was a true gift imo I Cbdpotential 11/03/17 03:42:23 PM
#3070   Starting to look like a gap fill move. Citrati 11/03/17 02:09:16 PM
#3069   This looks like a solid article on IDRA's Citrati 11/03/17 09:02:10 AM
#3068   k...anytime under $8.50. hold until the end noretreat 10/30/17 10:56:12 PM
#3067   Gotta be in it to win it. :-D Citrati 10/30/17 09:36:37 PM
#3066   Plan to hold for a while. Did noretreat 10/30/17 09:02:52 PM
#3065   IDRA up .14 to 1.75 in Citrati 10/30/17 06:38:21 PM
#3064   I'm in at an average of about 1.47. noretreat 10/27/17 01:37:46 PM
#3063   You summed it up nicely. I have Stockdoggy 10/26/17 06:05:17 PM
#3062   I’ve said that many times with this 1... Farmmarket1 10/26/17 05:33:45 PM
#3061   Thank you for posting. It is days Stockdoggy 10/26/17 05:29:48 PM
#3060   * * $IDRA Video Chart 10-26-17 * * ClayTrader 10/26/17 05:11:41 PM
#3059   Wow, that pricing of the shares was some Tlsmd 10/26/17 12:23:00 PM
#3058   Ouch. Condolences... :-( Citrati 10/26/17 12:17:38 PM
#3057   Looking to take a position here as it Pr0drIv3 10/26/17 12:15:48 PM
#3056   That is how I have always justified IDRA’s Farmmarket1 10/26/17 12:10:53 PM
#3055   If one is willing, the only way I Citrati 10/26/17 11:58:54 AM
#3054   Problem I see if the tutes are running Farmmarket1 10/26/17 11:44:34 AM
#3053   Thankyou Fm1. That illuminates a lot. Citrati 10/26/17 11:42:40 AM
#3052   Email from Doody Mr. Graham, Thank you for sending Farmmarket1 10/26/17 11:31:37 AM
#3051   I'm with you. I was trying to be Phantom Lord 10/26/17 11:03:00 AM
#3050   I will have to get into the filing Citrati 10/26/17 10:59:06 AM
#3049   I’m so damn pissed I can’t see straight.. Farmmarket1 10/26/17 10:13:42 AM
#3048   so is this a buying opportunity? Or noretreat 10/26/17 08:21:17 AM
PostSubject